121 related articles for article (PubMed ID: 35093762)
21. CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis.
Jilek S; Schluep M; Rossetti AO; Guignard L; Le Goff G; Pantaleo G; Du Pasquier RA
Clin Immunol; 2007 Apr; 123(1):105-13. PubMed ID: 17188575
[TBL] [Abstract][Full Text] [Related]
22. [Genome-Wide Analysis of DNA Methylation in Cd4+ T Lymphocytes of Patients with Primary Progressive Multiple Sclerosis Indicates Involvement of This Epigenetic Process in the Disease Immunopathogenesis].
Kiselev IS; Kulakova OG; Danilova LV; Baturina OA; Kabilov MR; Popova EV; Boyko AN; Favorova OO
Mol Biol (Mosk); 2022; 56(3):468-475. PubMed ID: 35621102
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.
Kivisäkk P; Healy BC; Viglietta V; Quintana FJ; Hootstein MA; Weiner HL; Khoury SJ
Neurology; 2009 Jun; 72(22):1922-30. PubMed ID: 19487650
[TBL] [Abstract][Full Text] [Related]
24. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
Hjorth M; Dandu N; Mellergård J
PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
[TBL] [Abstract][Full Text] [Related]
25. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
[TBL] [Abstract][Full Text] [Related]
26. Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression.
Ewing E; Kular L; Fernandes SJ; Karathanasis N; Lagani V; Ruhrmann S; Tsamardinos I; Tegner J; Piehl F; Gomez-Cabrero D; Jagodic M
EBioMedicine; 2019 May; 43():411-423. PubMed ID: 31053557
[TBL] [Abstract][Full Text] [Related]
27. Immunomonitoring measures in relapsing-remitting multiple sclerosis.
Matsui M; Araya SI; Wang HY; Matsushima K; Saida T
J Neuroimmunol; 2004 Mar; 148(1-2):192-9. PubMed ID: 14975601
[TBL] [Abstract][Full Text] [Related]
28. Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.
Fellay B; Chofflon M; Juillard C; Paunier AM; Landis T; Roth S; Gougeon ML
Immunology; 2001 Dec; 104(4):383-91. PubMed ID: 11899423
[TBL] [Abstract][Full Text] [Related]
29. Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells.
Tilly G; Cadoux M; Garcia A; Morille J; Wiertlewski S; Pecqueur C; Brouard S; Laplaud D; Degauque N
Front Immunol; 2021; 12():730342. PubMed ID: 34721394
[TBL] [Abstract][Full Text] [Related]
30. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
31. Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients.
Maltby VE; Graves MC; Lea RA; Benton MC; Sanders KA; Tajouri L; Scott RJ; Lechner-Scott J
Clin Epigenetics; 2015; 7():118. PubMed ID: 26550040
[TBL] [Abstract][Full Text] [Related]
32. INFβ treatment affects global DNA methylation in monocytes of patients with multiple sclerosis.
Diniz SN; da Silva CF; de Almeida IT; da Silva Costa FE; de Oliveira EML
J Neuroimmunol; 2021 Jun; 355():577563. PubMed ID: 33853016
[TBL] [Abstract][Full Text] [Related]
33. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
34. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
[TBL] [Abstract][Full Text] [Related]
35. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
36. CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis.
Sellebjerg F; Ross C; Koch-Henriksen N; Sørensen PS; Frederiksen JL; Bendtzen K; Sørensen TL
Mult Scler; 2005 Dec; 11(6):641-5. PubMed ID: 16320722
[TBL] [Abstract][Full Text] [Related]
37. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase.
Ochi H; Osoegawa M; Wu XM; Minohara M; Horiuchi I; Murai H; Furuya H; Kira J
J Neurol Sci; 2002 Sep; 201(1-2):45-51. PubMed ID: 12163193
[TBL] [Abstract][Full Text] [Related]
38. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol.
Soldan SS; Alvarez Retuerto AI; Sicotte NL; Voskuhl RR
J Immunol; 2003 Dec; 171(11):6267-74. PubMed ID: 14634144
[TBL] [Abstract][Full Text] [Related]
39. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
40. Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS.
Zastepa E; Fitz-Gerald L; Hallett M; Antel J; Bar-Or A; Baranzini S; Lapierre Y; Haegert DG
Neurology; 2014 Feb; 82(8):681-90. PubMed ID: 24453076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
